Gene Therapy Market – Global Outlook & Forecast 2021-2031

Gene Therapy Market – Global Outlook & Forecast 2021-2031

Gene Therapy Market Introduction

Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein. In order to insert new genes directly into cells, a vehicle called a “vector” is used which is genetically engineered to deliver the gene.

Market - Headwinds & Tailwinds

The global gene therapy market is mainly driven by rising prevalence of various chronic diseases such as cancer & rare genetic disorders, robust pipeline, and growing government initiatives. Furthermore, increasing investment for R&D activities to launch more effective therapy is also playing a pivotal role in contributing to the market growth globally. However, high cost of therapy is likely to hinder the market growth to a certain extent.

Gene Therapy Market Report

Market Segmentation & Insights

The global gene therapy market has been analyzed from four main perspectives: Vector Type, Delivery Method, Disease Indication and Region.

Gene Therapy Market by Vector Type

Based on vector type, the gene therapy market has been segmented into viral vector and non-viral vector. The viral vector segment is further categorized into adenovirus, retrovirus, lentivirus, adeno-associated virus, herpes simplex virus and others (poxvirus, vaccinia virus, etc.). Whereas, non-viral vector is further categorized into naked DNA, transfection, liposomes, nanoparticles and others (nucleofection, transposons, etc.). The non-viral vector segment is expected to be fastest growing segment during the forecast period owing to its advantages over viral vector. Non-viral vectors are safer, cheaper, more reproducible and do not present DNA size limit.

Gene Therapy Market by Delivery Method

Based on delivery method, the gene therapy market has been segmented into in vivo gene therapy and ex vivo gene therapy. Ex vivo gene therapy refers to the process of genetically altering a person’s cells outside of the body and then transplanting them back in. Whereas, In vivo gene therapy refers to direct administration either intravenously, known as systemic administration, or locally to a specific organ of interest. The ex vivo gene therapy segment holds the largest share in the market. The growth of the segment can be attributed to its wide application in hematopoietic stem cells (HSCs), which are relevant to blood & immunological diseases and genetic diseases that affect tissues and organs easily accessible by blood cells.

Gene Therapy Market by Disease Indication

Based on disease indication, the gene therapy market has been segmented into cancer, neurological diseases, rare diseases, cardiovascular diseases and others (infectious diseases, hepatological diseases, etc.). The cancer segment accounted for the largest share in the market. The growth of the segment can be attributed to the rising prevalence of different types of cancer all over the world coupled with the approval of different types of gene therapy for the treatment of cancer. Furthermore, presence of large number of gene therapy candidates in pipeline is also expected to boost the growth of the market in the forecast period.

Gene Therapy Market by Region

Based on region, the global gene therapy market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominated the gene therapy market, followed by Asia Pacific. The large share of North America in the global market can largely be attributed to the advanced healthcare infrastructure, presence of prominent players, rising prevalence of cancer in the region, rising investments in the R&D of gene therapy and robust therapy pipeline.

 Competitive Landscape

The gene therapy market is marked by presence of prominent players such Novartis AG, Amgen Inc., Gilead Sciences, Inc., Bayer AG, REGENXBIO Inc., uniQure N.V., Voyager Therapeutics, Spark Therapeutics, Inc., SIBIONO, and Orchard Therapeutics plc. Other players operating in the market are bluebird bio, Inc., Audentes Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, among others.

Snapshot: Industry Developments

  • In Mar 2021, SIRION Biotech signed a gene therapy collaboration with Sanofi to work with Heidelberg University Hospital’s Professor Dirk Grimm in Germany to develop next-generation tissue-selective adeno-associated virus (AAV) vectors for gene therapies
  • In Jan 2021, MeiraGTx announced that FDA granted fast track designation to its AAV-CNGA3, a gene therapy candidate for the treatment of achromatopsia
  • In Dec 2020, Neurogene Inc., announced that the European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to its adeno-associated virus vector (AAV) with engineered transgene encoding the human AGA gene for patients diagnosed with aspartylglucosaminuria
  • In Dec 2020, Janssen Pharmaceuticals, announced that it has acquired US-based biotechnology company Hemera Biosciences’ investigational gene therapy, HMR59, for the preservation of vision in patients with geographic atrophy, a form of age-related macular degeneration (AMD)

 

Key Insights Captured in the Report

  • Quantitative (market size and forecasts) and qualitative insights of the market across years - historical years, current year and forecasted years
  • Deep-rooted insights on headwinds, tailwinds and opportunities prevailing in the market
  • Quantitative (market size and forecasts) and qualitative insights at segment and sub-segment level
  • Comprehensive quantitative (market size and forecasts) and qualitative insights on geographic, regional and country level markets
  • Granular insights on the competitive landscape prevailing in the market
  • Competitive mapping of strategic developments 

Scope of the Gene Therapy Market Report:

Report Metrics Details
Market Size Period 2018-2031
Base Year 2020
Forecast Period 2021-2031
Market Segments Asessment of Gene Therapy Market By:
• Vector Type
• Delivery Method
• Disease Indication
• Region
Geographic Scope North America
◦ U.S.
◦ Canada
Europe
◦ Germany
◦ UK
◦ France
◦ Rest of Europe (RoE)
Asia Pacific
◦ China
◦ Japan
◦ India
◦ Rest of Asia Pacific (RoAPAC)
Rest of the World
◦ Latin America
◦ Middle East & Africa
Companies Covered Novartis AG, Amgen Inc., Gilead Sciences, Inc., Bayer AG, REGENXBIO Inc., uniQure N.V., Voyager Therapeutics, Spark Therapeutics, Inc., SIBIONO, and Orchard Therapeutics plc., bluebird bio, Inc., Audentes Therapeutics, Ionis Pharmaceuticals, Sarepta Therapeutics, among others.

1 RESEARCH ENVELOPE

1.1 Market Classification

1.2 Scope of the Study

1.2.1 Timeline Considered for Market Study

· Historic Years – 2018 & 2019

· Base Year – 2020

· Projected Years – 2021 to 2031

1.3 Currency Used in the Report

2 RESEARCH METHODOLOGY

2.1 Research Approach

2.2 Data Collection Methodology

2.3 Data Sources

2.3.1 Secondary Sources

2.3.2 Primary Sources

2.4 Market Crackdown Methodology

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Data Forecasting Model

2.6 Limitations and Assumptions for Study

3 HEADWINDS & TAILWINDS ASSESSMENT

4 MARKET OPPORTUNITIES ASSESSMENT

5 PREMIUM INSIGHTS

5.1 Key Market Trends

5.2 Key Players & Their Competitive Positioning (2020)

5.3 COVID-19 Impact Assessment

5.4 Pipeline Assessment

6 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY VECTOR TYPE

6.1 Viral Vector

6.1.1 Adenovirus

6.1.2 Retrovirus

6.1.3 Lentivirus

6.1.4 Adeno-Associated Virus

6.1.5 Herpes Simplex Virus

6.1.6 Others (Poxvirus, Vaccinia Virus, Etc.)

6.2 Non-Viral Vector

6.2.1 Naked DNA

6.2.2 Transfection

6.2.3 Liposomes

6.2.4 Nanoparticles

6.2.5 Others (Nucleofection, Transposons, Etc.)

7 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY DELIVERY METHOD

7.1 In Vivo Gene Therapy

7.2 Ex Vivo Gene Therapy

8 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY DISEASE INDICATION

8.1 Cancer

8.2 Neurological Diseases

8.3 Rare Diseases

8.4 Cardiovascular Diseases

8.5 Others (Infectious Diseases, Hepatological Diseases, Etc.)

9 GLOBAL GENE THERAPY MARKET - ANALYSIS & FORECAST, BY REGION

9.1 North America Gene Therapy Market

9.1.1 North America Gene Therapy Market, By Country

9.1.1.1 U.S.

9.1.1.2 Canada

9.1.2 North America Gene Therapy Market, By Vector Type

9.1.3 North America Gene Therapy Market, By Delivery Method

9.1.4 North America Gene Therapy Market, By Disease Indication

9.2 Europe Gene Therapy Market

9.2.1 Europe Gene Therapy Market, By Country/Region

9.2.1.1 Germany

9.2.1.2 U.K

9.2.1.3 France

9.2.1.4 Rest of Europe (ROE)

9.2.2 Europe Gene Therapy Market, By Vector Type

9.2.3 Europe Gene Therapy Market, By Delivery Method

9.2.4 Europe Gene Therapy Market, By Disease Indication

9.3 Asia Pacific Gene Therapy Market

9.3.1 Asia Pacific Gene Therapy Market, By Country/Region

9.3.1.1 China

9.3.1.2 Japan

9.3.1.3 India

9.3.1.4 Rest of Asia Pacific (RoAPAC)

9.3.2 Asia Pacific Gene Therapy Market, By Vector Type

9.3.3 Asia Pacific Gene Therapy Market, By Delivery Method

9.3.4 Asia Pacific Gene Therapy Market, By Disease Indication

9.4 Rest of the World (RoW) Gene Therapy Market

9.4.1 Rest of the World Gene Therapy Market, By Region

9.4.1.1 Latin America

9.4.1.2 Middle East & Africa

9.4.2 Rest of The World Gene Therapy Market, By Vector Type

9.4.3 Rest of The World Gene Therapy Market, By Delivery Method

9.4.4 Rest of The World Gene Therapy Market, By Disease Indication

10 COMPANY PROFILES

10.1 Novartis AG

10.1.1 Business Overview

10.1.2 Financial Metrics*

10.1.3 Product Portfolio

10.1.4 Key Developments

10.2 Amgen Inc.

10.3 Gilead Sciences, Inc.

10.4 Bayer AG

10.5 REGENXBIO Inc.

10.6 uniQure N.V.

10.7 Voyager Therapeutics

10.8 Spark Therapeutics, Inc.

10.9 SIBIONO

10.10 Orchard Therapeutics plc

*Insights on financial metrics is subject to availability of information in the public domain

Download Report Sample PDF

Specific Requirement Form

Solitary

  • The solitary license authorizes only one individual to use the report
  • A PDF version of the report will be delivered that can be viewed on only one authorized system
  • Buyers need to share the ‘Name and Email ID of the authorized user
  • Imitation, distribution as well as quoting of the contents of the report is prohibited without the prior permission of Clairvoyance Research

$4850

Compound

  • Compound license authorizes only 5 individuals to use the report
  •  A PDF/Printable version of report will be delivered that can be viewed on only 5 authorized systems
  • Free analyst support for 10 hours is extended as a value-added service
  • Buyers need to share ‘Names and Email IDs’ of the authorized users 
  • Imitation, distribution as well as quoting of the contents of the report is prohibited without the prior permission of Clairvoyance Research

$5850

Corporate

  • Corporate license authorizes unlimited individuals to use the report
  • A PDF/Printable version of report will be delivered that can be viewed on unlimited systems
  • Free analyst support for 30 hours is extended as a value-added service 
  • This license type allows the buyer to quote the contents of the report published by Clairvoyance Research

$6850

Data Pack

  • Data Pack’ request provides customers all ‘Quantitative Insights’ with respect to a particular market in an excel-based dashboard format

$2250

Purchase Options

Solitary $4850

Compound $5850

Corporate $6850

Data Pack $2250

  • The solitary license authorizes only one individual to use the report
  • A PDF version of the report will be delivered that can be viewed on only one authorized system
  • Buyers need to share the ‘Name and Email ID of the authorized user
  • Imitation, distribution as well as quoting of the contents of the report is prohibited without the prior permission of Clairvoyance Research

Popular Reports

Summer 3E,Purti Season,22 Buroshibtalla Main Road, Near Leela Petrol Pump, Kolkata, West Bengal-700038
+ 91 8761988338
10 AM to 10 PM
info@clairvoyanceresearch.com
Support line
TOP